Study guide

11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

Key Takeaways Explain This Topic AI

BPS includes non-malignant hematology in the BCOP target population; blueprint task 2A2 explicitly tests immune thrombocytopenia, aplastic anemia, and sickle cell disease pharmacotherapy.

ITP first-line therapy is a short corticosteroid course (dexamethasone 40 mg x 4 days) with IVIG for urgent counts; second-line therapy centers on TPO receptor agonists — eltrombopag must be separated from food, dairy, and cations by 4 hours.

Severe aplastic anemia is treated with matched-sibling allogeneic HSCT in young patients or with horse ATG + cyclosporine + eltrombopag triple immunosuppression (RACE-trial standard) when transplant-ineligible.

Hydroxyurea titrated to the maximum tolerated dose (MCV rise marks adherence) is first-line disease-modifying therapy in sickle cell disease; voxelotor was withdrawn worldwide in 2024, and gene therapies (exagamglogene autotemcel, lovotibeglogene autotemcel) are curative options for patients aged 12 and older.

TTP (ADAMTS13 activity <10%) requires emergent plasma exchange plus caplacizumab, corticosteroids, and rituximab; platelet transfusion is relatively contraindicated, and drug-induced TMA (gemcitabine, carfilzomib) is managed by drug withdrawal rather than PLEX.

Last updated: August 2026

1. Why Benign Hematology Is in the BCOP Scope

The BPS BCOP target population explicitly includes pharmacists who manage clinical situations associated with non-malignant hematology , and blueprint task 2A2 (Treatment of Non-Malignant Hematologic Disorders) names aplastic anemia, immune thrombocytopenia (ITP), and sickle cell disease as exemplars. In practice, oncology pharmacists own these disorders because they share drugs (rituximab, corticosteroids, eltrombopag), supportive-care infrastructure (transfusion services, chelation, infection prophylaxis), and diagnostic reasoning (is this cytopenia marrow invasion, chemotherapy effect, or a primary hematologic disease?) with malignant hematology.

2. Immune Thrombocytopenia (ITP)

Definition: isolated thrombocytopenia (platelets <100 x 10^9/L) without other cytopenias or an alternative cause; a diagnosis of exclusion. Always classify as primary or secondary (SLE, CLL/lymphoma, H. pylori, HCV, HIV, or drug-induced — vancomycin, heparin, and even some antineoplastics), because treating the driver treats the platelets.

Line Agents Board Pearls

First-line Dexamethasone 40 mg PO x 4 days (preferred over prolonged prednisone tapers) or prednisone 1 mg/kg/day Treat when platelets <20-30 x 10^9/L or bleeding; observation is acceptable above that in asymptomatic adults

Urgent (wet bleeding / platelets <10k) IVIG 1 g/kg x 1-2 days ; anti-Rh(D) immune globulin (Rh-positive, non-splenectomized only — boxed warning for intravascular hemolysis); high-dose IV corticosteroids; platelet transfusion reserved for life-threatening hemorrhage IVIG raises platelets within 24-48 h but the effect wanes in 2-4 weeks

Second-line TPO receptor agonists: eltrombopag 50 mg PO daily (empty stomach; separate from dairy, antacids, and divalent cations by 4 hours ; hepatotoxicity monitoring), romiplostim 1-10 mcg/kg SC weekly (titrate to platelets), avatrombopag 20-40 mg PO daily with food (no chelation issue) Eltrombopag food/cation chelation is a favorite exam trap

Second-line (immune) Rituximab 375 mg/m2 weekly x 4 (durable responses in ~20-30%); fostamatinib 100 mg PO BID (SYK inhibitor; hypertension, transaminitis) HBV screening before rituximab

Definitive Splenectomy (highest durable remission rate; defer >=1-2 years from diagnosis) Pre-splenectomy vaccines: pneumococcal, meningococcal (ACWY + B), and Hib — pharmacist-owned catch-up

3. Aplastic Anemia (AA)

Recognition: pancytopenia with a hypocellular marrow (<25-30% cellularity); exclude hypocellular MDS, paroxysmal nocturnal hemoglobinuria (clone testing), and drug/radiation exposure. Severity (Camitta): severe AA = marrow cellularity <25-30% plus at least two of ANC <500/mcL, platelets <20 x 10^9/L, or absolute reticulocyte count <20-40 x 10^9/L.

Young patients (<40-50 years) with a matched sibling donor: upfront allogeneic HSCT is curative and preferred.

Transplant-ineligible patients: immunosuppressive therapy (IST) with horse antithymocyte globulin (hATG) + cyclosporine + eltrombopag — adding eltrombopag upfront to hATG/cyclosporine (the RACE-trial regimen) improved complete and overall hematologic response rates and is the current standard triple regimen. Rabbit ATG is inferior for AA.

Supportive care: irradiated, leukoreduced blood products; minimize transfusions (especially from family members) in potential HSCT candidates to prevent alloimmunization; iron chelation (deferasirox) for transfusion iron overload; infection prophylaxis when severely neutropenic; single-agent G-CSF is not disease-modifying.